Papillary thyroid cancer differential diagnosis: Difference between revisions

Jump to navigation Jump to search
m (Reverted edits by Sabawoon Mirwais (talk) to last revision by Sahar Memar Montazerin)
Tag: Rollback
Line 16: Line 16:
{| border="3"
{| border="3"
|+  
|+  
! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF| Disease Name}}  
! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF| Disease name}}  
! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF| Age of Onset}}
! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF| Age of onset}}
! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF| Gender Preponderance}}
! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF| Gender preponderance}}
! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF| Signs/Symptoms}}
! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF| Signs/Symptoms}}
! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF| Imaging Feature(s)}}
! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF| Imaging Feature(s)}}
! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF| Macroscopic Feature(s)}}
! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF| Macroscopic feature(s)}}
! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF| Microscopic Feature(s)}}
! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF| Microscopic feature(s)}}
! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF| Laboratory Findings(s)}}  
! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF| Laboratory Feature(s)}}  
! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF| Other Feature(s)}}
! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF| Other Feature(s)}}
! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF| Microscopic Appearance}}
! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF| Microscopic appearance}}
|-
|-
! style="padding: 5px 5px; background: #DCDCDC; " align="left" |Papillary Thyroid Cancer<ref name="FaginMitsiades2008">{{cite journal|last1=Fagin|first1=James A.|last2=Mitsiades|first2=Nicholas|title=Molecular pathology of thyroid cancer: diagnostic and clinical implications|journal=Best Practice & Research Clinical Endocrinology & Metabolism|volume=22|issue=6|year=2008|pages=955–969|issn=1521690X|doi=10.1016/j.beem.2008.09.017}}</ref><ref name="Schlumberger1998">{{cite journal|last1=Schlumberger|first1=Martin Jean|title=Papillary and Follicular Thyroid Carcinoma|journal=New England Journal of Medicine|volume=338|issue=5|year=1998|pages=297–306|issn=0028-4793|doi=10.1056/NEJM199801293380506}}</ref><ref name="pmid20001718">{{cite journal |vauthors=Sipos JA |title=Advances in ultrasound for the diagnosis and management of thyroid cancer |journal=Thyroid |volume=19 |issue=12 |pages=1363–72 |date=December 2009 |pmid=20001718 |doi=10.1089/thy.2009.1608 |url=}}</ref>
! style="padding: 5px 5px; background: #DCDCDC; " align="left" |Papillary Thyroid Cancer<ref name="FaginMitsiades2008">{{cite journal|last1=Fagin|first1=James A.|last2=Mitsiades|first2=Nicholas|title=Molecular pathology of thyroid cancer: diagnostic and clinical implications|journal=Best Practice & Research Clinical Endocrinology & Metabolism|volume=22|issue=6|year=2008|pages=955–969|issn=1521690X|doi=10.1016/j.beem.2008.09.017}}</ref><ref name="Schlumberger1998">{{cite journal|last1=Schlumberger|first1=Martin Jean|title=Papillary and Follicular Thyroid Carcinoma|journal=New England Journal of Medicine|volume=338|issue=5|year=1998|pages=297–306|issn=0028-4793|doi=10.1056/NEJM199801293380506}}</ref><ref name="pmid20001718">{{cite journal |vauthors=Sipos JA |title=Advances in ultrasound for the diagnosis and management of thyroid cancer |journal=Thyroid |volume=19 |issue=12 |pages=1363–72 |date=December 2009 |pmid=20001718 |doi=10.1089/thy.2009.1608 |url=}}</ref>
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
* More common in the middle aged (30 - 50 years of age)
* More common in middle aged (30-50 years of age)
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
* More commonly affects women
* More commonly affects women
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
*[[Asymptomatic]] [[thyroid]] [[mass]] or [[nodule]]
*[[Asymptomatic]] [[thyroid]] [[mass]] or [[nodule]]
*Compressive [[symptoms]], such as:
*Compressive [[symptoms]] such as:
*[[Dysphagia|Difficulty swallowing]]/[[Dyspnea|breathing]]
*[[Dysphagia|Difficulty swallowing]]/[[Dyspnea|breathing]]
*Persistent [[cough]]
*Persistent [[cough]]
*[[Stridor]]
*[[Stridor]]
*[[Vocal cord|Vocal chord]] [[paralysis]]
*Vocal chord [[paralysis]]
*Rapid enlarging [[mass]]
*Rapid enlarging [[mass]]
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
* On [[ultrasound]]
*[[Ultrasound]]: solitary [[mass]] with an irregular outline, in the subcapsular region and with high [[vascularity]]
** [[Solitary]] [[mass]] with an irregular outline
*[[Imaging]] features are not characteristic for this [[cancer]]
** Located in the sub-capsular region
** High [[vascularity]]
 
*[[Imaging]] features are not characteristic of this [[cancer]]
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
*[[Solitary]] hypoechogenic [[nodule]] with [[Lobule|lobulated]] margin which may extend into adjacent [[tissues]]
* Solitary hypoechogenic [[nodule]] with lobulated margin which may extend into adjacent [[tissues]]
*[[Calcification]] may be present or not
*[[Calcification]] may be present or not
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
Line 54: Line 50:
*[[Psammoma body|Psammoma bodies]]
*[[Psammoma body|Psammoma bodies]]
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
*[[Thyroid function test|Thyroid function tests]] can be normal
*[[Thyroid function test]] may be normal
*Serum [[thyroglobulin]] can be used as a [[tumor marker]]
*[[Thyroglobulin]] may be used as a [[tumor marker]]
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
* History of [[radiation]] to the [[head]] and [[neck]]
* History of [[radiation]] in head and neck
*[[BRAF]] and/or [[RET gene|RET]] [[mutation]] may be present
*[[BRAF]] and/or [[RET gene|RET]] [[mutation]] may be present
*The most common type of thyroid cancer
*Most common type of [[thyroid cancer]]
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |[[Image:Thyroid papillary carcinoma histopathology (3).jpg|thumb|none|200px|Source:Wikimedia commons ]]
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |[[Image:Thyroid papillary carcinoma histopathology (3).jpg|thumb|none|200px|Source:Wikimedia commons ]]
|-
|-
! style="padding: 5px 5px; background: #DCDCDC; " align="left" |Follicular Thyroid Cancer<ref name="Schlumberger1998">{{cite journal|last1=Schlumberger|first1=Martin Jean|title=Papillary and Follicular Thyroid Carcinoma|journal=New England Journal of Medicine|volume=338|issue=5|year=1998|pages=297–306|issn=0028-4793|doi=10.1056/NEJM199801293380506}}</ref><ref name="pmid20001718">{{cite journal |vauthors=Sipos JA |title=Advances in ultrasound for the diagnosis and management of thyroid cancer |journal=Thyroid |volume=19 |issue=12 |pages=1363–72 |date=December 2009 |pmid=20001718 |doi=10.1089/thy.2009.1608 |url=}}</ref><ref name="pmid2019455">{{cite journal |vauthors=Pettersson B, Adami HO, Wilander E, Coleman MP |title=Trends in thyroid cancer incidence in Sweden, 1958-1981, by histopathologic type |journal=Int. J. Cancer |volume=48 |issue=1 |pages=28–33 |date=April 1991 |pmid=2019455 |doi=10.1002/ijc.2910480106 |url=}}</ref>
! style="padding: 5px 5px; background: #DCDCDC; " align="left" |Follicular Thyroid Cancer<ref name="Schlumberger1998">{{cite journal|last1=Schlumberger|first1=Martin Jean|title=Papillary and Follicular Thyroid Carcinoma|journal=New England Journal of Medicine|volume=338|issue=5|year=1998|pages=297–306|issn=0028-4793|doi=10.1056/NEJM199801293380506}}</ref><ref name="pmid20001718">{{cite journal |vauthors=Sipos JA |title=Advances in ultrasound for the diagnosis and management of thyroid cancer |journal=Thyroid |volume=19 |issue=12 |pages=1363–72 |date=December 2009 |pmid=20001718 |doi=10.1089/thy.2009.1608 |url=}}</ref><ref name="pmid2019455">{{cite journal |vauthors=Pettersson B, Adami HO, Wilander E, Coleman MP |title=Trends in thyroid cancer incidence in Sweden, 1958-1981, by histopathologic type |journal=Int. J. Cancer |volume=48 |issue=1 |pages=28–33 |date=April 1991 |pmid=2019455 |doi=10.1002/ijc.2910480106 |url=}}</ref>
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
* Peak [[incidence]] at 40 - 60 years of age
* Peak [[incidence]] is 40-60 years of age
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
* More commonly affects women
* More commonly affects women
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
*[[Asymptomatic]] [[thyroid]] [[mass]] or [[nodule]]
*[[Asymptomatic]] [[thyroid]] [[mass]] or [[nodule]]
*Compressive [[symptoms]], such as:
*Compressive [[symptoms]] such as:
*[[Difficulty swallowing]]/[[Dyspnea|breathing]]
*[[Difficulty swallowing]]/[[Dyspnea|breathing]]
*Persistent [[cough]]
*Persistent [[cough]]
*[[Stridor]]
*[[Stridor]]
*[[Vocal cord|Vocal chord]] [[paralysis]]
*Vocal chord [[paralysis]]
*Rapid enlarging [[mass]]
*Rapid enlarging [[mass]]
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
* On [[ultrasound]]:
* [[Ultrasound]]: solid hypoechoic [[nodule]] with a peripheral halo indicating [[fibrous capsule]]
**Solid hypoechoic [[nodule]] with a peripheral halo indicating [[fibrous capsule]]
* Irregular margin
**Irregular margin
* [[Imaging]] features are not characteristic for this [[cancer]]
*[[Imaging]] features are not characteristic of this [[cancer]]
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
* Single encapsulated [[nodule]]
* Single encapsulated [[nodule]],
* Thick and irregular [[capsule]]
* Thick and irregular [[capsule]]
* Can be [[cystic]] or [[hemorrhage|hemorrhagic]] in appearance
* May have [[cystic]] or [[hemorrhage]]
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
* Invades [[thyroid]] [[capsule]] and [[vasculature]]
* Invades [[thyroid]] [[capsule]] and [[vasculature]]
* Uniform [[Follicle|follicles]] <br />
* Uniform [[Follicle|follicles]] <br />
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
*[[Thyroid function test|Thyroid function tests]] can be normal
*[[Thyroid function test]] may be normal
* Serum [[thyroglobulin]] can be used as a [[tumor marker]]
* Serum [[thyroglobulin]] may be used as a [[tumor marker]]
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
*[[RASA3|RAS]] [[mutation]] may be present
*[[RASA3|RAS]] [[mutation]] may be present
*[[PAX8]]-[[PPAR|PPARγ]] [[Translocation|translocations]]
* PAX8-PPAR [[Translocation|translocations]]
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |[[Image:Metastatic follicular thyroid carcinoma - Case 264.jpg|thumb|none|200px|Source:Wikimedia common ]]
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |[[Image:Metastatic follicular thyroid carcinoma - Case 264.jpg|thumb|none|200px|Source:Wikimedia common ]]
|-
|-
Line 99: Line 94:
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
*[[Incidence]] increases with age
*[[Incidence]] increases with age
* More common in the 3rd to 4th decades of life
* More common in 3rd to 4th decades of life
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
* Both genders are affected equally
* Both genders affected equally
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
*[[Solitary]] [[thyroid nodule]]
* Solitary [[thyroid nodule]]
* Mostly affects upper [[Lobe (anatomy)|lobe]] of [[thyroid gland]]
* Mostly affects upper lobe of thyroid gland
* Possible [[systemic]] [[symptoms]] due to [[Hormone|hormonal]] [[secretion]] by the [[tumor]]
* Possible [[systemic]] [[symptoms]] due to hormonal secretion by the [[tumor]]
*[[Cervical]] [[lymphadenopathy]]
*[[Cervical]] [[lymphadenopathy]]
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
*On [[ultrasound]]:
*[[Ultrasound]]: solitary hypoechoic [[nodule]] with or without [[calcification]]
**[[Solitary]] hypoechoic [[nodule]] with or without [[calcification]]
*Imaging features are not characteristic for this [[cancer]]
*[[Imaging]] features are not characteristic of this [[cancer]]
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
* Single non-encapsulated mass
* Single nonencapsulated [[mass]]
* Gray-tan color
* Gray-tan color
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
* Sheets of [[cells]] in an [[amyloid]] [[stroma]]
* Sheets of [[cells]] in an [[amyloid]] [[stroma]]
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
*[[Secretion|Secretes]] [[calcitonin]]
* Secretes [[calcitonin]]
*Normal [[thyroid function test|thyroid function tests]]
*Normal [[thyroid function test]]
*[[Carcinoembryonic antigen]] ([[CEA]]) may be used as a [[tumor marker]]
*[[Carcinoembryonic antigen]] ([[CEA]]) may be used as a [[tumor marker]]
*Rarely negative for [[calcitonin]]
*Rarely negative for [[calcitonin]]
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
* Can be part of [[MEN syndromes|MEN 2A]] and [[Multiple endocrine neoplasia type 2|2B syndrome]]
* May be part of [[MEN syndromes|MEN 2A]] and [[Multiple endocrine neoplasia type 2|2B syndrome]]
* Can be associated with [[RET gene|RET]] [[mutation]]
* May be associated with [[RET gene|RET]] [[mutation]]
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |[[File:Thyroid MedullaryCarcinoma SpindleCell LP PA.JPG|thumb|none|200px|Source:Wikimedia common ]]
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |[[File:Thyroid MedullaryCarcinoma SpindleCell LP PA.JPG|thumb|none|200px|Source:Wikimedia common ]]
|-
|-
Line 129: Line 123:
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
* More common among older individuals
* More common among older individuals
*[[Mean]] age at [[diagnosis]] is 65 years
*Mean age at [[diagnosis]] is 65 years
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
* More commonly affects women
* More commonly affects women
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
* Rapidly enlarging [[thyroid]] [[mass]]
* Rapidly enlarging thyroid [[mass]]
* May manifest with compressive [[symptoms]]
* May manifest with compressive [[symptoms]]
*Can present with [[signs]]/[[symptoms]] of [[metastasis]]
*May present with [[signs]]/[[symptoms]] of [[metastasis]]
*Constitutional [[symptoms]] may be present
*Constitutional [[symptoms]] may be present
*Hard [[Nodule (medicine)|nodular]] [[goiter]] without [[tenderness]]
*Hard nodular [[goiter]] w/out [[tenderness]]
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
* On [[ultrasound]]:
[[Ultrasound]]: solid hypoechoic [[nodule]] with a peripheral halo indicating [[fibrous capsule]]
** Solid hypoechoic [[nodule]] with a peripheral halo indicating [[fibrous capsule]]
* Irregular margin
 
* [[Imaging]] features are not characteristic for this [[cancer]]
** Irregular margin
*[[Imaging]] features are not characteristic of this [[cancer]]
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
* Solid [[tumor]] with areas of [[necrosis]] and [[hemorrhage]]
* Solid [[tumor]] with areas of [[necrosis]] and [[hemorrhage]]
*[[Infiltration (medical)|Infiltrative]] pattern
* Infiltrative pattern
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
* Undifferentiated, devastatingly aggressive variant of [[Papillary thyroid cancer|papillary]]/[[follicular thyroid cancer]]
* Undifferentiated, devastatingly aggressive variant of Papillary/[[Follicular thyroid cancer]]
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
* Normal [[thyroid function test|thyroid function tests]]
* Normal [[thyroid function test]]
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
* Poor [[prognosis]]
* Poor [[prognosis]]
Line 197: Line 189:
* Some may show [[papillary]] [[Projection areas|projections]] without [[nuclear]] characteristics of [[papillary thyroid cancer]]
* Some may show [[papillary]] [[Projection areas|projections]] without [[nuclear]] characteristics of [[papillary thyroid cancer]]
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
*[[Classification|Classified]] as toxic and non-toxic
* Classified as toxic and non-toxic
**'''Toxic:''' [[Hyperthyroidism]]
* Toxic =>  hyperthyroidism
**'''Non-toxic:''' Normal [[thyroid function test|thyroid function tests]]
* Non-toxic => Normal [[thyroid function test]]
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
*[[Benign]] [[condition]]
*[[Benign]] [[condition]]
Line 207: Line 199:
<ref name="pmid3141260">{{cite journal |vauthors=Hyjek E, Isaacson PG |title=Primary B cell lymphoma of the thyroid and its relationship to Hashimoto's thyroiditis |journal=Hum. Pathol. |volume=19 |issue=11 |pages=1315–26 |date=November 1988 |pmid=3141260 |doi=10.1016/s0046-8177(88)80287-9 |url=}}</ref><ref name="pmid3759532">{{cite journal |vauthors=Tupchong L, Hughes F, Harmer CL |title=Primary lymphoma of the thyroid: clinical features, prognostic factors, and results of treatment |journal=Int. J. Radiat. Oncol. Biol. Phys. |volume=12 |issue=10 |pages=1813–21 |date=October 1986 |pmid=3759532 |doi=10.1016/0360-3016(86)90324-x |url=}}</ref><ref name="pmid17042683">{{cite journal |vauthors=Ota H, Ito Y, Matsuzuka F, Kuma S, Fukata S, Morita S, Kobayashi K, Nakamura Y, Kakudo K, Amino N, Miyauchi A |title=Usefulness of ultrasonography for diagnosis of malignant lymphoma of the thyroid |journal=Thyroid |volume=16 |issue=10 |pages=983–7 |date=October 2006 |pmid=17042683 |doi=10.1089/thy.2006.16.983 |url=}}</ref>
<ref name="pmid3141260">{{cite journal |vauthors=Hyjek E, Isaacson PG |title=Primary B cell lymphoma of the thyroid and its relationship to Hashimoto's thyroiditis |journal=Hum. Pathol. |volume=19 |issue=11 |pages=1315–26 |date=November 1988 |pmid=3141260 |doi=10.1016/s0046-8177(88)80287-9 |url=}}</ref><ref name="pmid3759532">{{cite journal |vauthors=Tupchong L, Hughes F, Harmer CL |title=Primary lymphoma of the thyroid: clinical features, prognostic factors, and results of treatment |journal=Int. J. Radiat. Oncol. Biol. Phys. |volume=12 |issue=10 |pages=1813–21 |date=October 1986 |pmid=3759532 |doi=10.1016/0360-3016(86)90324-x |url=}}</ref><ref name="pmid17042683">{{cite journal |vauthors=Ota H, Ito Y, Matsuzuka F, Kuma S, Fukata S, Morita S, Kobayashi K, Nakamura Y, Kakudo K, Amino N, Miyauchi A |title=Usefulness of ultrasonography for diagnosis of malignant lymphoma of the thyroid |journal=Thyroid |volume=16 |issue=10 |pages=983–7 |date=October 2006 |pmid=17042683 |doi=10.1089/thy.2006.16.983 |url=}}</ref>
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
* Affects [[Adult|adults]] or elderly
* Affects adults or elderly
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
* More common among women
* More common among women
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
* Rapidly enlarging mass/[[nodule]] of [[thyroid]]
* Rapidly enlarging [[mass]]/ [[nodule]] of [[thyroid]]
* Compressive [[symptoms]] may be present
* Compression [[symptoms]] may be present
* [[B symptoms|Constitiutional symptoms]] can be present in 10%
* [[B symptoms|Constitiutional symptoms]] may be present in 10%
*[[Physical examination|P/E]]:Firm, hard [[thyroid]]
* P/E:Firm, hard [[thyroid]]
* Fixed to the nearby structures
* Fixed to the nearby structure
* Immobile even during swallowing
* Immobile even during swallowing
* [[Cervical]] or [[supraclavicular]] [[lymphadenopathy]] may be present
* [[Cervical]] or [[supraclavicular]] [[lymphadenopathy]] may be present


| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
* On [[ultrasound]]:
* [[Ultrasound]]: hypoechogenic appearance difficult to be distinguished from chronic [[thyroiditis]]
**Hypoechogenic appearance
**Difficult to distinguish from [[Chronic (medical)|chronic]] [[thyroiditis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
* [[Thyroid nodule]]/mass
* [[Thyroid nodule]]/[[mass]] fixing to adjacent [[tissue]] with a firm texture
*Fixed to adjacent [[tissue]]
*Firm texture
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
* It is of [[B cell]] lineage in the majority of cases
* It is of [[B cell]] lineage in the majority of cases
* Dffuse, large [[B-cell lymphoma|B-cell lymphomas]] is the most common subtype
* Dffuse, large [[B-cell lymphoma|B-cell lymphomas]] is the most common subtype: diffuse infiltrate of B cells destroying thyroid follicles
* [[Marginal zone lymphoma]] is the second most common type
* [[Marginal zone lymphoma]] is the second most common type
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
* No specific test
* No specific test
* Some [[Patient|patients]] may have [[hypothyroidism]]
* Some may have [[hypothyroidism]]
*[[Patient|Patients]] can also have [[antibody|antibodies]] against [[thyroid peroxidase]] or [[thyroglobulin]]
* Some may have [[antibody]] against [[thyroid peroxidase]] or [[thyroglobulin]]  
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
* Preexisting [[Chronic (medical)|chronic]] [[Hashimoto's thyroiditis|autoimmune (Hashimoto's) thyroiditis]] is a known [[risk factor]] for this [[condition]]
* Preexisting chronic [[Hashimoto's thyroiditis|autoimmune (Hashimoto's) thyroiditis]] is a known [[risk factor]] for this [[condition]]
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |[[File:Thyroid lymphoma large cell type fine needle aspiration biop.jpeg|thumb|none|200px|Source:pathology outline, case courtesy of Dr. Mark R. Wick]]
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |[[File:Thyroid lymphoma large cell type fine needle aspiration biop.jpeg|thumb|none|200px|Source:pathology outline, case courtesy of Dr. Mark R. Wick]]
|}
|}
==Reference==
==Reference==
{{Reflist|2}}
{{Reflist|2}}

Revision as of 23:51, 1 August 2019

Papillary thyroid cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Papillary thyroid cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Papillary thyroid cancer differential diagnosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Papillary thyroid cancer differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Papillary thyroid cancer differential diagnosis

CDC on Papillary thyroid cancer differential diagnosis

Papillary thyroid cancer differential diagnosis in the news

Blogs on Papillary thyroid cancer differential diagnosis

Directions to Hospitals Treating Papillary thyroid cancer

Risk calculators and risk factors for Papillary thyroid cancer differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2] Sahar Memar Montazerin, M.D.[3]

Overview

Papillary thyroid cancer must be differentiated from other diseases that cause neck mass, such as branchial cleft cyst, thyroglossal duct cyst, cystic metastasis, and multiple neurofibromas.

Differentiating Papillary thyroid cancer from other Diseases

  • Other thyroid neoplasms should be considered in the absence of cavitary cervical lymph nodes.[1]
  • The differential of a cystic neck mass(es) includes:
Disease name Age of onset Gender preponderance Signs/Symptoms Imaging Feature(s) Macroscopic feature(s) Microscopic feature(s) Laboratory Feature(s) Other Feature(s) Microscopic appearance
Papillary Thyroid Cancer[2][3][4]
  • More common in middle aged (30-50 years of age)
  • More commonly affects women
Source:Wikimedia commons
Follicular Thyroid Cancer[3][4][5]
  • More commonly affects women
Source:Wikimedia common
Medullary Thyroid Cancer[6][7][8][4]
  • Incidence increases with age
  • More common in 3rd to 4th decades of life
  • Both genders affected equally
  • Single nonencapsulated mass
  • Gray-tan color
Source:Wikimedia common
Anaplastic Thyroid Cancer[9][10][11]
  • More common among older individuals
  • Mean age at diagnosis is 65 years
  • More commonly affects women

Ultrasound: solid hypoechoic nodule with a peripheral halo indicating fibrous capsule

  • Irregular margin
  • Imaging features are not characteristic for this cancer
Source:Wikimedia common
Follicular Adenoma[12]
  • More commonly affects individuals older than 50 years of age
  • More commonly affects women
  • Solitary nodule which may show echogenicity or not
  • Solitary, spherical, and encapsulated lesion
  • Well demarcated from the surrounding parenchyma
  • Functional adenoma:
    • Elevated T3, T4
    • Decreased TSH
  • May be considered functional or hot
  • May be considered non-functional or cold
Source:Wikimedia common
Multinodular Goiter[13]
  • Commonly affects individuals older than 60 years of age
  • More commonly affects women
Source:pathology outline, case courtesy of Dr. Swati Satturwar
Thyroid Lymphoma[14]

[15][16][17]

  • Affects adults or elderly
  • More common among women
  • It is of B cell lineage in the majority of cases
  • Dffuse, large B-cell lymphomas is the most common subtype: diffuse infiltrate of B cells destroying thyroid follicles
  • Marginal zone lymphoma is the second most common type
Source:pathology outline, case courtesy of Dr. Mark R. Wick

Reference

  1. Accessed on November, 4 2015 "Papillary thyroid cancer [Dr Yuranga Weerakkody and Dr Frank Gaillard et al.].Radiopedia 2015" Check |url= value (help).
  2. Fagin, James A.; Mitsiades, Nicholas (2008). "Molecular pathology of thyroid cancer: diagnostic and clinical implications". Best Practice & Research Clinical Endocrinology & Metabolism. 22 (6): 955–969. doi:10.1016/j.beem.2008.09.017. ISSN 1521-690X.
  3. 3.0 3.1 Schlumberger, Martin Jean (1998). "Papillary and Follicular Thyroid Carcinoma". New England Journal of Medicine. 338 (5): 297–306. doi:10.1056/NEJM199801293380506. ISSN 0028-4793.
  4. 4.0 4.1 4.2 Sipos JA (December 2009). "Advances in ultrasound for the diagnosis and management of thyroid cancer". Thyroid. 19 (12): 1363–72. doi:10.1089/thy.2009.1608. PMID 20001718.
  5. Pettersson B, Adami HO, Wilander E, Coleman MP (April 1991). "Trends in thyroid cancer incidence in Sweden, 1958-1981, by histopathologic type". Int. J. Cancer. 48 (1): 28–33. doi:10.1002/ijc.2910480106. PMID 2019455.
  6. Busnardo B, Girelli ME, Simioni N, Nacamulli D, Busetto E (January 1984). "Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinoma". Cancer. 53 (2): 278–85. doi:10.1002/1097-0142(19840115)53:2<278::aid-cncr2820530216>3.0.co;2-z. PMID 6690009.
  7. Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH (March 2000). "Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems". Cancer. 88 (5): 1139–48. doi:10.1002/(sici)1097-0142(20000301)88:5<1139::aid-cncr26>3.0.co;2-z. PMID 10699905.
  8. Hofstra, Robert M. W.; Landsvater, Rudy M.; Ceccherini, Isabella; Stulp, Rein P.; Stelwagen, Tineke; Luo, Yin; Pasini, Barbara; Hoppener, Jo W. M.; van Amstel, Hans Kristian Ploos; Romeo, Giovanni; Lips, Cornells J. M.; Buys, Charles H. C. M. (1994). "A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma". Nature. 367 (6461): 375–376. doi:10.1038/367375a0. ISSN 0028-0836.
  9. Nagaiah G, Hossain A, Mooney CJ, Parmentier J, Remick SC (2011). "Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment". J Oncol. 2011: 542358. doi:10.1155/2011/542358. PMC 3136148. PMID 21772843.
  10. Chang TC, Liaw KY, Kuo SH, Chang CC, Chen FW (June 1989). "Anaplastic thyroid carcinoma: review of 24 cases, with emphasis on cytodiagnosis and leukocytosis". Taiwan Yi Xue Hui Za Zhi. 88 (6): 551–6. PMID 2794956.
  11. Venkatesh YS, Ordonez NG, Schultz PN, Hickey RC, Goepfert H, Samaan NA (July 1990). "Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases". Cancer. 66 (2): 321–30. doi:10.1002/1097-0142(19900715)66:2<321::aid-cncr2820660221>3.0.co;2-a. PMID 1695118.
  12. Mathur, Aarti; Olson, Matthew T.; Zeiger, Martha A. (2014). "Follicular Lesions of the Thyroid". Surgical Clinics of North America. 94 (3): 499–513. doi:10.1016/j.suc.2014.02.005. ISSN 0039-6109.
  13. Bronshteĭn ME, Makarov AD, Artemova AM, Bazarova EN, Kozlov GI (1994). "[Morphology of the thyroid tissue in multinodular euthyroid goiter]". Probl Endokrinol (Mosk) (in Russian). 40 (2): 36–9. PMID 8197088.
  14. Pedersen RK, Pedersen NT (January 1996). "Primary non-Hodgkin's lymphoma of the thyroid gland: a population based study". Histopathology. 28 (1): 25–32. PMID 8838117.
  15. Hyjek E, Isaacson PG (November 1988). "Primary B cell lymphoma of the thyroid and its relationship to Hashimoto's thyroiditis". Hum. Pathol. 19 (11): 1315–26. doi:10.1016/s0046-8177(88)80287-9. PMID 3141260.
  16. Tupchong L, Hughes F, Harmer CL (October 1986). "Primary lymphoma of the thyroid: clinical features, prognostic factors, and results of treatment". Int. J. Radiat. Oncol. Biol. Phys. 12 (10): 1813–21. doi:10.1016/0360-3016(86)90324-x. PMID 3759532.
  17. Ota H, Ito Y, Matsuzuka F, Kuma S, Fukata S, Morita S, Kobayashi K, Nakamura Y, Kakudo K, Amino N, Miyauchi A (October 2006). "Usefulness of ultrasonography for diagnosis of malignant lymphoma of the thyroid". Thyroid. 16 (10): 983–7. doi:10.1089/thy.2006.16.983. PMID 17042683.